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Key	research	questions	to	be	addressed	include:	1. What	are	the	patient	characteristics	and	clinical	features	of	CAP	in	adults	in	sub-Saharan	Africa	in	general	and	in	Malawi	in	particular?		2. What	are	the	common	microbial	causes	of	CAP	in	these	settings?	3. What	clinical	factors	evident	at	presentation	predict	adverse	outcome?	4. Do	CAP-severity	assessment	tools	derived	in	well-resourced	settings	accurately	identify	individuals	at	risk	of	adverse	outcome?	5. Are	there	potentially	modifiable	risk	factors	for	adverse	outcome	that	are	rational	targets	for	therapeutic	interventions	to	improve	CAP	outcome?	
This	thesis	sets	out	to	address	these	questions	in	the	following	studies:	
1. A	prospective	observational	study	of	adults	hospitalised	with	CAP	to	Queen	Elizabeth	Central	Hospital	called	the	Malawian	Lower	Respiratory	Tract	Infection,	Severity,	Aetiology	and	Outcome	(MARISO)	Study.	The	key	objectives	were:		a. To	determine	the	frequency	of	30-day	mortality	and	treatment	failure	in	adults	hospitalised	with	clinically	diagnosed	CAP;	b. To	identify	the	clinical	and	basic	diagnostic	laboratory	characteristics	associated	with	30-day	mortality	and	treatment	failure;	c. To	describe	the	microbial	aetiology	using	modern	diagnostic	modalities.		
Introduction:	CAP	in	sub-Saharan	Africa	 46	








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Community-based	studies	(Gilks	et	al.,	1996)	 Kenya	 		 		 		 		 		 		 		 		 		 		(Mwachari	et	al.,	2006)	 Kenya	 		 		 		 		 		 		 		 		 		 		
Hospital-based	studies	(Zoubga	et	al.,	2000)	 Burkina	Faso	 		 		 		 		 		 		 		 		 		 		(Ouedraogo	et	al.,	2010)	 Burkina	Faso	 		 		 		 		 		 		 		 		 		 		(Koulla-Shiro	et	al.,	1994)	 Cameroon	 		 		 		 		 		 		 		 		 		 		(Koulla-Shiro	et	al.,	1997)	 Cameroon	 		 		 		 		 		 		 		 		 		 		(Yone	et	al.,	2012)	 Cameroon	 		 		 		 		 		 		 		 		 		 		(Vray	et	al.,	2008)	 CAR	 		 		 		 		 		 		 		 		 		 		(Coulibaly	et	al.,	1986)	 Cote	d'Ivoire	 		 		 		 		 		 		 		 		 		 		(Domoua	et	al.,	1993)	 Cote	d'Ivoire	 		 		 		 		 		 		 		 		 		 		(Koffi	et	al.,	1997)	 Cote	d’Ivoire	 		 		 		 		 		 		 		 		 		 		(Koffi	et	al.,	2001)	 Cote	d’Ivoire	 		 		 		 		 		 		 		 		 		 		(Horo	et	al.,	2009)	 Cote	d’Ivoire	 		 		 		 		 		 		 		 		 		 		(Aderaye,	1994a)	 Ethiopia	 		 		 		 		 		 		 		 		 		 		(Ahmedtaha	et	al.,	2014)	 Ethiopia	 		 		 		 		 		 		 		 		 		 		(Slack	et	al.,	1976)	 Kenya	 		 		 		 		 		 		 		 		 		 		(Scott	et	al.,	2000)	 Kenya	 		 		 		 		 		 		 		 		 		 		(French	et	al.,	2002)	 Kenya	 		 		 		 		 		 		 		 		 		 		(Odera	et	al.,	2009)	 Kenya	 		 		 		 		 		 		 		 		 		 		(Rakotoson	et	al.,	2010)	 Madagascar	 		 		 		 		 		 		 		 		 		 		(Harries	et	al.,	1988a)	 Malawi	 		 		 		 		 		 		 		 		 		 		(Gordon	et	al.,	2002)	 Malawi	 		 		 		 		 		 		 		 		 		 		(Birkhamshaw	et	al.,	2013)	 Malawi	 		 		 		 		 		 		 		 		 		 		(Bos	et	al.,	2014)	 Mozambique	 		 		 		 		 		 		 		 		 		 		(Sofowora	et	al.,	1973)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Awunor-Renner,	1979)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Fiberesima	et	al.,	2008)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Onyedum	et	al.,	2011)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Mbata	et	al.,	2013)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Sow	et	al.,	1996)	 Rep.	of	Guinea	 		 		 		 		 		 		 		 		 		 		(Sire	et	al.,	2010)	 Senegal	 		 		 		 		 		 		 		 		 		 		(Prout	et	al.,	1983)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Maartens	et	al.,	1994)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Feldman	et	al.,	1996)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Feldman	et	al.,	1999)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Mpe	et	al.,	2001)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Charalambous	et	al.,	2003)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Schleicher	et	al.,	2005)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Nyamande	et	al.,	2007a)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Xaba	et	al.,	2014)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Albrich	et	al.,	2012)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Roe,	1968)	 Uganda	 		 		 		 		 		 		 		 		 		 		(Yoshimine	et	al.,	2001)	 Uganda	 		 		 		 		 		 		 		 		 		 		(El-Amin,	1978)	 Zambia	 		 		 		 		 		 		 		 		 		 			
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Hospital-based	studies	(Zoubga	et	al.,	2000)	 Burkina	Faso	 Inpatient	 10/106	 9.4		(3.9-15.0)	(Ouedraogo	et	al.,	2010)	 Burkina	Faso	 Inpatient	 52/239	 21.8		(16.5-27.0)	(Koulla-Shiro	et	al.,	1994)	 Cameroon	 Inpatient	 0/43	 0		(0-4.3)	
(Koulla-Shiro	et	al.,	1997)	 Cameroon	 Inpatient	 7/91	 7.7		(2.2-13.2)	(Yone	et	al.,	2012)	 Cameroon	 Inpatient	 13/106	 12.3		(6.0-18.5)	(Vray	et	al.,	2008)	 CAR	 21	days	 15/95	 15.8		(8.5-23.1)	(Domoua	et	al.,	1993)	 Cote	d’Ivoire	 Inpatient	 12/52	 23.1		(11.6-34.5)	(Koffi	et	al.,	1997)	 Cote	d’Ivoire	 Inpatient	 5/96	 5.2		(0.8-9.7)	(Koffi	et	al.,	2001)	 Cote	d’Ivoire	 Inpatient	 5/100	 5.0		0.7-9.3)	(Horo	et	al.,	2009)	 Cote	d'Ivoire	 3	days	 3/50	 6.0		(0-12.6)	
(Aderaye,	1994a)	 Ethiopia	 6-8	weeks	 11/110	 10.0		(4.4-15.6)	(Ahmedtaha	et	al.,	2014)	 Ethiopia	 Inpatient	 21/104	 20.2		(12.5-27.9)	
(Slack	et	al.,	1976)	 Kenya	 Inpatient	 2/105	 1.9		(0-4.5)	
(Scott	et	al.,	2000)	 Kenya	 3	weeks	 25/255	 9.8		(6.2-13.5)	(French	et	al.,	2002)	 Kenya	 Inpatient	 12/122	 9.8		(4.6-15.1)	
(Rakotoson	et	al.,	2010)	 Madagascar	 Inpatient	 2/96	 2.1		(0-4.9)	(Harries	et	al.,	1988b)	 Malawi	 Inpatient	 1/100	 1.0		(0-3.0)	(Gordon	et	al.,	2002)	 Malawi	 Inpatient	 18/92	 19.6		(11.5-27.7)	(Birkhamshaw	et	al.,	2013)	 Malawi	 Inpatient	 43/235	 18.3		(13.4-23.2)	(Sofowora	et	al.,	1973)	 Nigeria	 Inpatient	 20/88	 22.7		(14.0-31.5)	(Awunor-Renner,	1979)	 Nigeria	 Radiological	resolution	 0/73	 0		(0-2.5)	(Fiberesima	et	al.,	2008)	 Nigeria	 21	days	 4/53	 7.5		(0-14.7)	(Onyedum	et	al.,	2011)	 Nigeria	 Inpatient	 19/160	 11.9		(6.9-16.9)	
(Mbata	et	al.,	2013)	 Nigeria	 30	days	 12/80	 15.0		(7.2-22.8)	(Sow	et	al.,	1996)	 Rep.	of	Guinea	 Inpatient	 13/218	 6.0		(2.8-9.1)	(Sire	et	al.,	2010)	 Senegal	 21	days	 13/68	 19.1		(9.8-28.5)	(Prout	et	al.,	1983)	 South	Africa	 Inpatient		(min.	14	days)	 3/81	 3.7		(0-7.8)	
(Feldman	et	al.,	1996)	 South	Africa	 Inpatient	 1/47	 2.1		(2.0-6.3)	(Feldman	et	al.,	1999)	 South	Africa	 Inpatient	 4/94	 4.3		(0-8.3)	
(Mpe	et	al.,	2001)	 South	Africa	 Inpatient	 15/123	 12.2		(6.4-18.0)	(Charalambous	et	al.,	2003)	 South	Africa	 Inpatient		(min.	14	days)	 5/124	 4.0		(0.1-7.5)	
(Schleicher	et	al.,	2005)	 South	Africa	 Inpatient	 1/33	 3.0		(0-8.9)	
(Nyamande	et	al.,	2007a)	 South	Africa	 Inpatient	 73/430	 17.0		(13.4-20.5)	(Xaba	et	al.,	2014)	 South	Africa	 Inpatient	 39/200	 19.5		(14.0-25.0)	
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Physiological	observations	 	 	Temperature	(°C)	<35	or	≥40	 37.9	14/459	 (37.1-38.9)	(3.1)	Systolic	blood	pressure	(mmHg)	<90	 106	86/454	 (93-121)	(18.9)	Diastolic	blood	pressure	(mmHg)	≤60	 68	143/454	 (59-78)	(31.5)	Systolic	<90	and/or	diastolic	blood	pressure	≤60	(mmHg)	 	160/454	 	(35.2)	Heart	rate	(beats/min)	≥125	 118	176/458	 (102-132)	(38.4)	Respiratory	rate	(breaths/min)	≥30		 29	213/446	 (26-34)	(47.8)	Oxygen	saturations	(%)	≤90	<90	
95	
101/449	
73/449	 (91-98)	(22.5)	(16.3)	Body	mass	index	(kg/m2)	<18.5	 19.9	132/444	 (18.2-21.8)	(29.7)	Mid-upper	arm	circumference	(mm)	<230mm	 250	118/451	 (220-260)	(26.2)	










n	 Detailed	initial	regimen	 n	 Final	treatment	summary	 n	




3	2	2	1	1	1	Pen.	&	Chloram.	 100	 -	 	 Pen.	&	Chloram.	Ceftriax.,	Pen.	&	Chloram.	Ceftriax.	Pen.,	Chloram.&	Amox.	Ceftriax.	&	Amox.	Pen.,	Chloram.,	Amox.	&	Atypical	Ceftriax.,	Pen.,	Chloram.	&	Amox.	Ceftriax.,	Pen.	&	Gent.	

















S.	pneumonia	 5/450	 (1.1)	 4/350	 (1.1)	 1/94	 (1.1)	
S.	typhi	 9/450	 (2.0)	 3/350	 (0.9)	 5/94	 (5.3)	
S.	Typhimurium	 6/450	 (1.3)	 6/350	 (1.7)	 0/94	 (0)	
S.	Enteritidis	 1/450	 (0.2)	 1/350	 (0.3)	 0/94	 (0)	
S.	aureus	 2/450	 (0.4)	 1/350	 (0.3)	 1/94	 (1.1)	
E.	coli	 2/450	 (0.4)	 2/350	 (0.6)	 0/94	 (0)	
E.	cloacae	 1/450	 (0.2)	 1/350	 (0.3)	 0/94	 (0)	
Pleural	fluid	culture	
S.	typhi	 1/31	 (3.2)	 1/19	 (5.3)	 0/11	 (0)	
M.	tuberculosis	 7/35	 (20.0)	 4/22	 (18.2)	 2/12	 (16.7)	
S.	pneumoniae	antigen	test	Urine	 95/433	 (21.9)	 67/333	 (20.1)	 28/94	 (29.8)	Pleural	fluid	 3/31	 (9.7)	 1/20	 (5)	 2/10	 (20)	
Sputum	mycobacterial	diagnostic	tests	AFB	smear	microscopy	 36/305	 (11.8)	 30/241	 (12.4)	 6/60	 (10.0)	
Sputum	culture	









Multiplex	PCR	on	nasopharyngeal	aspirate	Adenovirus	 35/455	 (7.7)	 30/355	 (8.5)	 5/98	 (5.1)	Bocavirus	 13/455	 (2.9)	 13/355	 (3.6)	 0/98	 (0)	
C.	pneumoniae	 2/455	 (0.4)	 0/355	 (0)	 2/98	 (2)	Coronavirus	HKU	 3/455	 (0.7)	 3/355	 (0.9)	 0/98	 (0)	Coronavirus	229	 19/455	 (4.2)	 16/355	 (4.5)	 3/98	 (3.1)	Coronavirus	43	 6/455	 (1.3)	 6/355	 (1.7)	 0/98	 (0)	Coronavirus	63	 5/455	 (1.4)	 5/355	 (1.4)	 0/98	 (0)	Enterovirus	 5/455	 (1.1)	 5/355	 (1.4)	 0/98	 (0)	Influenza	A	 19/454	 (4.2)	 13/354	 (3.7)	 5/98	 (5.1)	Influenza	B	 21/454	 (4.6)	 17/354	 (4.8)	 4/98	 (4.1)	
Legionella	spp.	 84/455	 (18.5)	 62/355	 (17.5)	 20/98	 (20.4)	Metapneumovirus	 9/455	 (2)	 8/355	 (2.3)	 1/98	 (1.0)	





























































































































































































































































































































































































































































































































































































































































S.	pneumoniae	 40	 0	 0	 0	 0	 0	 7	 2	 6	 7	 5	 4	 6	 1	 3	 2	 0	 0	 73	
S.	typhi	 	 2	 0	 0	 0	 0	 1	 1	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 4	NTS	 	 	 2	 0	 0	 0	 0	 2	 0	 1	 1	 1	 0	 0	 0	 0	 0	 0	 5	Other	GNEB	 	 	 	 0	 0	 0	 0	 0	 0	 0	 1	 0	 0	 0	 0	 0	 0	 0	 1	
S.	aureus	 	 	 	 	 0	 0	 0	 0	 1	 0	 0	 0	 0	 0	 0	 0	 0	 0	 1	Atypical	bacteria	 	 	 	 	 	 1	 1	 0	 0	 0	 0	 1	 0	 0	 0	 0	 0	 0	 3	
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Respiratory	rate	(/min)	 	 	≥20	 62/417	(14.9)	 100	(94.2-100)	 2.5	(1.1-4.6)	 -	≥25	 52/334	(15.6)	 83.9	(72.3-92.0)	 22.5	(18.3-27.2)	 1.51	(0.74-3.11)	≥30	 33/205	(16.1)	 53.2	(40.1-66.0)	 52.7	(47.5-58.0)	 1.27	(0.74-2.18)	≥35	 15/95	(15.8)	 24.2	(14.2-36.7)	 78.0	(73.4-82.2)	 1.13	(0.60-2.13)	≥40	 5/40	(12.5)	 8.1	(2.7-17.8)	 90.4	(86.9-93.2)	 0.82	(0.31-2.19)	≥45	 1/20	(5.0)	 1.6	(0-8.7)	 94.8	(92.0-96.8)	 0.30	(0.04-2.26)	
Heart	rate	(/min)	 	 	≥80	 62/416	(14.9)	 96.9	(89.2-99.6)	 5.3	(3.3-8.1)	 1.75	(0.40-7.68)	≥90	 59/383	(15.4)	 92.2	(82.7-97.4)	 13.4	(10.1-17.2)	 1.82	(0.70-4.75)	≥100	 58/346	(16.8)	 90.6	(80.7-96.5)	 23.0	(18.8-27.6)	 2.38	(1.20-6.92)	≥110	 49/285	(17.2)	 76.6	(64.3-86.2)	 36.9	(32.0-42.0)	 1.91	(1.03-3.53)	≥120	 45/213	(21.1)	 70.3	(56.6-81.1)	 55.1	(49.9-60.2)	 2.90	(1.64-5.15)	≥125	 37/172	(21.5)	 57.8	(44.8-70.1)	 63.9	(58.8-68.8)	 2.43	(1.42-4.16)	≥130	 26/131	(19.9)	 40.6	(28.5-53.6)	 71.9	(67.1-76.4)	 1.75	(1.01-3.03)	≥140	 12/54	(22.2)	 18.8	(10.1-30.5)	 88.8	(85.1-91.8)	 1.82	(0.90-3.69)	
Systolic	blood	pressure	(mmHg)	 	 	<115	 51/290	(17.6)	 81.0	(69.1-89.8)	 35.6	(30.7-40.7)	 2.34	(1.21-4.56)	<110	 45/255	(17.7)	 71.4	(58.7-82.1)	 43.4	(38.3-8.1)	 1.92	(1.07-3.44)	<105	 39/211	(18.5)	 61.9	(48.8-73.9)	 53.6	(48.4-58.8)	 1.88	(1.09-3.25)	<100	 32/166	(19.3)	 50.8	(37.9-63.6)	 63.9	(58.8-68.8)	 1.83	(1.07-3.12)	<95	 23/121	(19.0)	 36.5	(24.7-49.6)	 73.6	(68.8-78.0)	 1.60	(0.91-2.81)	<90	 17/83	(20.5)	 27.0	(16.6-39.7)	 82.2	(77.9-86.0)	 1.71	(0.92-3.16)	<85	 11/54	(20.4)	 17.5	(9.1-29.1)	 88.4	(84.7-91.5)	 1.61	(0.78-3.33)	<80	 7/23	(30.4)	 11.1	(4.6-21.6)	 95.7	(93.1-97.5)	 2.77	(1.09-7.04)	










































































































































































































































































































































































































































































































































































































































































































































































































































Demographics	 	 	Male	sex	 39	 (66.1)	Age	 38	 (31-59)	Current	smoker	 11	 (18.6)	

















Standard	flow-rate	(≤5	L/min		 (All	patients;	n=59)	Baseline	SpO2	(median(IQR))	 87	(81-89)	SpO2	≥92%	at	60	mins	(n(%))	 51	(86.4)	Average	Δ	SpO2	(mean±SD)	 10.3	±5.6	Max	Δ	SpO2	(mean±SD)	 12.1	±5.3	












RR	(95%	CI)	 P	Male	sex	 33	 (64.7)	 6	 (75)	 1.54	(0.34-6.94)	 0.57	
Age	(yrs)	 38	 (30-59)	 41	 (33-66)	 -	 0.61	Current	smoker	 10	 (19.6)	 1	 (12.5)	 0.62	(0.09-4.56)	 0.63	HIV-positive	 32/49	 (65.3)	 5	 (62.5)	 0.90	(0.24-3.39)	 0.88	Inability	to	stand	 20	 (39.2)	 7	 (87.5)	 8.30	(1.09-63.28)	 0.01	
Symptom	duration	(days)	 14	 (7-21)	 11	 (3-18)	 -	 0.26	
Systolic	BP	(mmHg)	 103	 (89-120)	 93	 (78-113)	 -	 0.21	
Diastolic	BP	(mmHg)	 67	 (54-82)	 66	 (60-84)	 -	 0.74	
Heart	rate	(/min)	 119	 (109-132)	 133	 (143-141)	 -	 0.32	
Respiratory	rate	(/min)	 40	 (36-47)	 40	 (34-53)	 -	 1.00	
Oxygen	saturations	(%)	 88	 (84-89)	 78	 (76-82)	 -	 <0.001	










































































































































































































































































































Study	design	 ☐	 Mortality	 ☐	
Pneumonia	 ☐	 Risk	factors	 ☐	













































Sex	 	 	 	 	 		
Age		 	 	 	 	 	
Smoking	status		 	 	 	 	 	
HIV	positive	 	 	 	 	 	
Chronic	lung	disease	 	 	 	 	 	
Chronic	heart	
disease	
	 	 	 	 	
Chronic	renal	failure	 	 	 	 	 	
Neurological	disease	 	 	 	 	 	
Confusion	 	 	 	 	 	
Heart	rate	 	 	 	 	 	
Respiratory	rate	 	 	 	 	 	
Hypoxia	 	 		 	 	 	
Hypotension	 			 	 		 	 	
Pyrexia	and/or	
pyrexia	
	 	 	 	 	
Cavitation	 	 	 	 	 	
Multilobar	
involvement	
		 		 		 		 	
Urea	 		 		 		 	 	
Haemoglobin	 	 	 	 	 	
White	cell	count	 		 		 		 	 		
CD4	cell	count	 	 	 	 	 	
Blood	culture	
positivity	
	 	 	 	 	
CURB65	≥3		 	 	 	 	 	
CRB65	≥3	 	 	 	 	 	
PSI	≥4	 	 	 	 	 	
PSI	≥5	 	 	 	 	 	









Blood	 ☐	 	 	
Spontaneous	sputum	 ☐	 	 	
Induced	sputum	 ☐	 	 	
Bronchoalveolar	lavage	 ☐	 	 	


















































If	any	of	the	above	PRESENT,	assign	high	risk	of	bias.	 Low	risk	 	 High	risk	 	
3. Assessment	of	outcome1	
Loss	to	follow	is	less	than	10%	of	total	cohort	 	






































































                                        
Burden and Severity of HIV-Associated Influenza Illness in Malawi (BASH-FLU) 
Malawian Adult Lower Respiratory Tract Infection Severity, Aetiology and Outcome Study (MARISO) 
H1N1 Influenza Surveillance 
Patient Consent Form, Version 5a (English); 12th March 2014 
 
THE COLLEGE OF MEDICINE 
Malawi-Liverpool-Wellcome Trust  







PATIENT CONSENT FORM  
BURDEN AND SEVERITY OF HIV-ASSOCIATED INFLUENZA ILLNESS IN MALAWI  
MALAWIAN ADULT LOWER RESPIRATORY TRACT INFECTION SEVERITY, 
AETIOLOGY AND OUTCOME STUDY 
H1N1 INFLUENZA SURVEILLANCE 
Statement by patient (tick boxes as appropriate): 
 Yes No 
I have read/been read the information sheet(s) for the BASH-FLU study (Version 3; 16thJune 
2013), the MARISO study (Version 6; 12th March 2014), and the H1N1 influenza surveillance 
(version; June 2013) (delete as appropriate). I have had the opportunity to ask questions 
about this study and I am satisfied with the answers that I have been given.  
□ □ 
I understand that even after agreeing to take part now, I can withdraw at any time, without 
giving a reason and without this affecting my medical care. 
□ □ 
I agree that the information collected about me during this study may be looked at by the 
study staff and also individuals from regulatory authorities. I give permission for these 
individuals to have access to my medical records including x-rays.  
□ □ 
I agree that samples of my blood, sputum, nasal, saliva and chest fluid and urine may be 
collected for the purpose of this study. I understand that some of my samples may be stored 
for analysis later or shipped overseas for tests that cannot be done in Malawi. 
□ □ 
I voluntarily agree to take part in the BASH-FLU study.  □ □ 
I voluntarily agree also to take part in the MARISO study. □ □ 
I voluntarily agree also to take part in the H1N1 influenza surveillance. □ □ 
 
Name of participant Date Signature/Thumbprint 
   
*Name of witness Date Signature/Thumbprint 
   
*Witnessed consent will be adequate in the case of patients unable to sign their own name. Witnesses must 






                                        
Burden and Severity of HIV-Associated Influenza Illness in Malawi (BASH-FLU) 
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Patient Consent Form, Version 5a (English); 12th March 2014 
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Malawi-Liverpool-Wellcome Trust  








   □      Statement by the researcher taking consent: 
The patient information document(s) for this study has been read by/been read out to the potential study 
participant. To the best of my ability I have ensured that the participant understands 
1. The reasons for the study 
2. The sampling and follow-up arrangements for participation 
3. Plans for protection of confidential data and dissemination of results 
 
I confirm that the participant was given an opportunity to ask questions about the study, and all questions 
have been answered correctly and to the best of my ability. I confirm that consent has been given freely and 
voluntarily. 
 
A copy of the consent form and patient information document has been given to the patient to keep. 
 
 
Name of Researcher Date Signature 
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THE COLLEGE OF MEDICINE 
Malawi-Liverpool-Wellcome Trust  
Clinical Research Programme 
Page1 
VERBAL ASSENT FORM  
ADDRESSING HYPOXAEMIA IN ADULT PNEUMONIA IN MALAWI 
Statement by study team member: 
 
______________________________________ (name of participant) or his/her guardian has given 
verbal indication of his/her willingness for his/her preliminary enrolment in the clinical study 
‘Addressing hypoxaemia in adult pneumonia in Malawi.’  
I have explained the purpose of the study and the main risks and benefits of taking part. I have 
specifically stated the following: 
x We would like patients to participate in this research study for us to learn the best way of 
providing oxygen for adults with pneumonia with low oxygen levels.  
x The study involves giving participants extra oxygen to breathe and carefully monitoring their 
oxygen levels. 
x We will also record some details from the medical history and take a small amount of blood 
for laboratory tests.  
x All participants will also receive the standard treatment for pneumonia provided by this 
hospital. 
x This research has been checked and approved by an independent committee to make sure 
that the potential benefits out weight the risks. 
x The risks of being in the study are expected to be low, and all participants are being 
monitored carefully for any harm. 
x All participation in research is voluntary so patients can refuse to take part and will still get 
the treatment for pneumonia recommended in this hospital. 
 
Name of participant Date Signature/Thumbprint 
   
Name of guardian Date Signature/Thumbprint 
   
*Name of witness Date Signature 
   
Name of researcher Date Signature 
   
*A witness will be used for patients/guardians unable to sign their own name. Witnesses must be mentally 
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THE COLLEGE OF MEDICINE 
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PATIENT CONSENT FORM  
ADDRESSING HYPOXAEMIA IN ADULT PNEUMONIA IN MALAWI 
Statement by patient:  
 Tick boxes 
as 
appropriate    
I have read/been read and understood the information sheet for the study (Version 
4; 9th March 2015). I have had the opportunity to ask questions about this study and 
I am satisfied with the answers that I have been given.  
 
I understand that information about me is to be used for the purposes indicated in 
the information sheet and I have been informed of all types of information that will 
be collected.  
 
I have been informed of the risks and benefits of participation in this study.  
I understand that even after agreeing to take part now, I can withdraw at any time, 
without giving a reason and without this affecting my medical care.   
I agree that the information collected about me during this study may be looked at 
by the study staff, researchers at MLW, Liverpool School of Tropical Medicine and 
also individuals from regulatory authorities. 
 
I agree that samples of my blood may be taken for the purposes indicated in the 
information sheet.  
I understand that if I come to harm as a participant in this study I can claim 
appropriate compensation from the study team without this affecting my clinical 
care 
 
I voluntarily agree to take part in the study.  
I do not wish to continue to take part in this study and request that all 
information collected about me to date is destroyed.  
 
Name of participant Date Signature/Thumbprint 
   
*Name of witness Date Signature/Thumbprint 
   
*A witness will be used for patients/guardians unable to sign their own name. Witnesses must be mentally 
competent adults over 18 years old who have no involvement with the research project 
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Statement by the researcher taking consent: 
The patient information document(s) for this study has been read by/been read out to the potential 
study participant. To the best of my ability I have ensured that the participant understands 
1. The reasons for the study 
2. The sampling and follow-up arrangements for participation 
3. Plans for protection of confidential data and dissemination of results 
 
I confirm that the participant was given an opportunity to ask questions about the study, and all 
questions have been answered correctly and to the best of my ability. I confirm that consent has 
been given freely and voluntarily. 
 




Name of Researcher Date Signature 
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